tizanidine extended release

Tizanidine extended release is an investigational oral formulation of tizanidine hydrochloride developed by Sun Pharma Advanced Research Company (SPARC). It is a centrally acting alpha-2 adrenergic agonist that acts as a skeletal muscle relaxant by inhibiting excitatory interneurons in the spinal cord, thereby reducing muscle spasticity and tone. The extended-release formulation, typically studied at a 12 mg dose, aims to provide a more sustained pharmacokinetic profile compared to immediate-release tizanidine, potentially reducing side effects like sedation while maintaining efficacy for conditions such as acute musculoskeletal pain and spasticity. A Phase 2 clinical trial in the Netherlands has evaluated its effects on simulated driving performance and cognitive function.

Other names

tizanidine hydrochloride extended releasetizanidine ER